Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore function in New Zealand. Its lead product is NTCELL, an alginate coated capsule, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease. The company was founded in 1987 and is based in Auckland, New Zealand.
living cell technologies ltd
(LCT:Australian Stock Exchange Ltd)
PO Box 23566
Phone: 64 9 276 2690
Fax: 64 9 276 2691www.lctglobal.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for LCT.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact LIVING CELL TECHNOLOGIES LTD, please visit www.lctglobal.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.